- Celltrion’s 2nd quarter operating profit was 72.49 billion won.
- Analysts had estimated an operating profit of 77.62 billion won.
- Net profit for the quarter was 78.01 billion won.
- The estimate for net profit was 68.74 billion won, surpassing expectations.
- Total sales reached 874.74 billion won.
- This exceeded the anticipated sales of 799.93 billion won.
- Shares of Celltrion rose by 9%, now priced at 0.2 million won.
- A total of 1.06 million shares were traded during the period.
- Market analyst ratings include 22 buys, 1 hold, and 1 sell.
Celltrion Inc on Smartkarma
Analyst coverage of Celltrion Inc on Smartkarma indicates positive sentiment from top independent analysts. Douglas Kim‘s insight on alpha generation through share buybacks highlights Celltrion Inc as one of the major companies in Korea engaging in share buybacks, representing 1.7% of outstanding shares. Brian Freitas suggests Celltrion could replace KT&G in the FnGuide Top 5 Plus Index, with high probability at the next rebalance, potentially impacting trading activities. Tina Banerjee‘s analysis of Celltrion’s 1Q24 results emphasizes strong sales growth of over 23% driven by Remsima in Europe, with profit expected to improve in the future. Her earlier report on Celltrion’s performance in 2023 and growth projections for 2024 showcases the company’s solid performance and ambitious sales targets.
A look at Celltrion Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Celltrion Inc, a company specializing in biosimilar products and consignment processing services, shows a promising long-term outlook based on the Smartkarma Smart Scores. With a Growth score of 3 and a Resilience score of 3, the company demonstrates potential for future development and the ability to withstand market challenges. Additionally, Celltrion Inc exhibits strong Momentum with a score of 4, indicating positive market trends and investor interest. While the Value and Dividend scores are lower at 2 each, suggesting room for improvement in these areas, the overall outlook for Celltrion Inc appears favorable for long-term growth and sustainability.
Celltrion Inc‘s main product, Abatacept, used for arthritis treatment, positions the company within the healthcare sector with a focus on providing innovative solutions for medical conditions. Leveraging its expertise in biosimilar products, along with its consignment processing services, Celltrion Inc aims to drive advancements in the pharmaceutical industry while meeting the healthcare needs of patients. With a balanced combination of growth potential, market resilience, and positive momentum, Celltrion Inc is poised to navigate future opportunities and challenges effectively, offering investors a promising outlook for sustainable returns.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
